Approximately 7 % of melanomas have a BRAF mutation beyond codon 600. These mutations can be BRAF activating without being addressable by an approved BRAF inhibitor. The case of a patient with fulminant metastatic melanoma and a BRAFL597Q mutation is presented. It is demonstrated that the tumor shows an excellent response to the MEK inhibitor trametinib. This is an example for possible targeted therapy in a non-V600-mutated melanoma resulting in a 17-month overall survival.
|Translated title of the contribution||Response of BRAFL597Q-mutant melanoma to trametinib: Targeted melanoma therapy beyond BRAFV600 mutations|
|Number of pages||5|
|Publication status||Published - 01.08.2016|
Research Areas and Centers
- Research Area: Luebeck Integrated Oncology Network (LION)